Joseph Slattery Purchases 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock

ImageneBio, Inc. (NASDAQ:IMA) Director Joseph Slattery purchased 16,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was acquired at an average cost of $5.99 per share, for a total transaction of $95,840.00. Following the completion of the purchase, the director owned 16,000 shares of the company’s stock, valued at approximately $95,840. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ImageneBio Stock Up 10.9%

Shares of IMA stock opened at $7.11 on Wednesday. The firm has a 50 day moving average of $7.20 and a 200-day moving average of $10.91. The company has a market cap of $79.49 million, a price-to-earnings ratio of -0.88 and a beta of 0.44. ImageneBio, Inc. has a 52 week low of $5.70 and a 52 week high of $20.40.

ImageneBio (NASDAQ:IMA) last issued its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($1.44). Analysts anticipate that ImageneBio, Inc. will post -0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after buying an additional 29,369 shares during the last quarter. Vanguard Group Inc. purchased a new stake in shares of ImageneBio in the third quarter valued at about $1,902,000. BML Capital Management LLC purchased a new stake in shares of ImageneBio in the third quarter valued at about $1,487,000. Aldebaran Capital LLC bought a new position in shares of ImageneBio during the third quarter valued at about $159,000. Finally, Blue Owl Capital Holdings LP purchased a new position in ImageneBio during the third quarter worth about $4,409,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analysts Set New Price Targets

IMA has been the subject of a number of research analyst reports. Wall Street Zen lowered ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Wedbush downgraded ImageneBio from a “neutral” rating to an “underperform” rating in a report on Tuesday, November 25th. Leerink Partners started coverage on ImageneBio in a report on Friday, October 24th. They issued an “outperform” rating and a $30.00 target price on the stock. Weiss Ratings started coverage on shares of ImageneBio in a research report on Wednesday, October 22nd. They issued a “sell (e-)” rating for the company. Finally, Leerink Partnrs upgraded shares of ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, ImageneBio has a consensus rating of “Hold” and an average target price of $26.50.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.